Table 1. Demographics.
| Variables | Europe (n=1232) | Japan (n=655) | Egypt (n=998) | Hong Kong (n=145) | All (n=3030) |
|---|---|---|---|---|---|
| % Male | 83.12, n=1232 | 74.66, n=655 | 83.27, n=998 | 85.52, n=145 | 81.45, n=2769 |
| Age (median, IQR) | 66.48 (59.00–73.18), n=1230 | 65.00 (58.00–73.00), n=655 | 57.00 (51.00–62.00), n=998 | 65.00 (56.00–71.00), n=145 | 62.77 (55.00–70.07), n=3028 |
| Albumin, g l−1 (median, IQR) | 37.00 (33.00–41.00), n=1214 | 32.00 (28.00–36.00), n=653 | 33.00 (29.00–37.00), n=998 | 35.00 (32.00–39.00), n=145 | 35.00 (30.00–39.00), n=3010 |
| Bilirubin, μmol l−1 (median, IQR) | 16.00 (10.94–26.00), n=1213 | 15.39 (11.97–23.94), n=653 | 22.23 (13.68–32.49), n=998 | 14.00 (9.00–22.00), n=145 | 17.10 (11.97–27.36), n=3009 |
| Tumour size, cm (median, IQR) | 5.00 (3.40–7.60), n=1180 | 3.50 (2.20–5.40), n=594 | 6.00 (4.00–8.00), n=998 | 6.00 (3.80–10.00), n=141 | 5.00 (3.40–7.60), n=2913 |
| % Multifocal | 66.24, n=1161 | 69.27, n=654 | 75.75, n=998 | 58.33, n=144 | 69.73, n=2957 |
| AFP, ng ml−1 (median, IQR) | 46.00 (6.70–534.50), n=1045 | 45.45 (12.40–510.00), n=614 | 129.00 (17.00–600.00), n=998 | 92.00 (10.00–1365.00), n=145 | 70.45 (11.00–584.00), n=2802 |
| INR (median, IQR) | 1.10 (1.01–1.20), n=851 | NA | 1.40 (1.20–1.70), n=998 | 1.14 (1.07–1.22), n=145 | 1.20 (1.10–1.40), n=1994 |
| ALBI score (median, IQR) | −2.34 (−2.72 to −1.91), n=1203 | −1.97 (−2.36 to −1.55), n=653 | −1.91 (−2.34 to −1.55), n=998 | −2.29 (−2.59 to −1.90), n=145 | −2.10 (−2.53 to −1.67), n=2999 |
| % ALBI grade (1 : 2 : 3) | 32.09 : 60.93 : 6.98, n=1203 | 13.02 : 70.75 : 16.23, n=653 | 15.63 : 69.14 : 15.23, n=998 | 24.83 : 67.59 : 7.59, n=145 | 22.11 : 66.12 : 11.77, n=2999 |
| % Child-Pugh (A : B : C) | 73.94 : 24.62 : 1.45, n=1174 | 52.06 : 41.22 : 6.72, n=655 | 47.60 : 46.89 : 5.51, n=998 | 77.24 : 21.38 : 1.38, n=145 | 60.43 : 35.60 : 3.97, n=2972 |
| % HAP class (A : B: C: D) | 18.72 : 34.42 : 31.95 : 14.91, n=892 (Liverpool, Birmingham, Germany and Spain only) | 13.49 : 32.40 : 38.53 : 15.59, n=571 | 9.02 : 22.55 : 41.08 : 27.35, n=998 | 12.06 : 37.59 : 29.79 : 20.57, n=141 | 13.49 : 29.59 : 36.78 : 20.14, n=2602 |
| % Vascular invasion | 10.61, n=1225 | 30.28, n=654 | 10.32, n=998 | 11.03, n=145 | 14.79, n=3022 |
| % HCV : HBV : other | 24.29 : 12.19 : 63.52, n=1165 | 56.66 : 18.42 : 24.92, n=646 | 98.39 : 1.10 : 0.50, n=996 | 8.33 : 79.86 : 11.81, n=144 | 55.61 : 13.11 : 31.28, n=2951 |
| Overall survival (months, 95% CI) | 16.6 (15.4–18.0), n=1226 | 22.3 (20–24.5), n=655 | 18.0 (17.0–19.0), n=998 | 19.9 (14.2–25.6), n=143 | 18.6 (17.9–19.5), n=3022 |
Abbreviations: AFP=alphafetoprotein; ALBI=Albumin-Bilirubin; CI=confidence interval.